Immune-health
Sovleplenib Phase III Data Show Durable Hemoglobin Response in AIHA
HUTCHMED's spleen tyrosine kinase inhibitor advances clinical evidence base as targeted hematology therapies draw renew…
HUTCHMED's spleen tyrosine kinase inhibitor advances clinical evidence base as targeted hematology therapies draw renew…